靶向GARP的CAR-T细胞平台治疗胶质母细胞瘤
本研究分析人胶质瘤数据库中GARP表达与临床结局的相关性,并对人GBM样本进行多重成像以了解GARP对肿瘤微环境的影响。研究开发了新型抗GARP CAR-T细胞疗法,在免疫健全同系和免疫缺陷小鼠的原位GBM模型中验证其疗效。结果显示GARP高表达与总生存差、间质亚型及血管生成和免疫排斥基因特征相关,抗GARP CAR-T在体外和体内(包括PDX模型)有效且无明显毒性。
要点
- 人GBM中GARP高表达与总生存差、间质亚型及免疫排斥微环境相关
- 新型抗GARP CAR-T在多种临床前GBM模型(含PDX)中有效且无明显毒性
- 针对复发GBM的首次人体I期临床试验已于2025年5月开始入组(NCT06964737)
核心结论
- GARP-LTGFβ在GBM发生和预后中起关键作用,靶向GARP的CAR-T疗法在小鼠原位GBM模型中显示出有希望的疗效和安全性。
研究设计与样本
- 研究分析多个人胶质瘤数据库以关联GARP表达与临床结局,并对人GBM样本进行多重成像。
- 研究开发新型抗GARP CAR-T细胞,在免疫健全同系和免疫缺陷小鼠的原位GBM模型(含PDX)中评估疗效。
主要发现
- 人GBM中GARP表达升高与总生存差、间质亚型及血管生成和免疫排斥相关基因特征相关。
- 新型抗GARP CAR-T在体外和体内对多种临床前GBM模型(包括PDX模型)有效,且无明显毒性。
临床怎么用
- GARP可作为GBM的潜在治疗靶点,抗GARP CAR-T是值得进一步临床转化的候选策略。
- 针对复发GBM的首次人体I期临床试验(NCT06964737)已于2025年5月开始入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glycoprotein A-repetitions predominant (GARP) is a cell surface non-signaling receptor for docking and activating latent transforming growth factor beta (LTGFβ) expressed by regulatory T cells, platelets, and tumor cells. In lung and breast cancers, its expression correlates with advanced stage and poor prognosis-suggesting that GARP could act as a therapeutic target. This study examines the therapeutic impact of targeting GARP in glioblastoma (GBM) via a novel anti-GARP chimeric antigen receptor-expressing T cell (CAR-T) modality in murine models of GBM. METHODS: We examined multiple human glioma databases to correlate the expression of GARP with clinical outcomes. We then performed multi-plex imaging of human GBM samples to understand the impact of GARP expression on the tumor microenvironment (TME). Importantly, we developed a novel anti-GARP CAR-T cell strategy to treat GBM. We examine if this therapy is efficacious against orthotopic models of GBM, in both immunocompetent syngeneic and immunodeficient mice. RESULTS: We demonstrate that elevated GARP expression in human GBM correlates with poor overall survival, mesenchymal subtype, and gene signatures associated with angiogenesis and immune exclusion in the TME. Our novel anti-GARP CAR-T is efficacious in vitro and in vivo, against multiple preclinical models of GBM, including patient-derived xenograft (PDX) models without significant toxicity. CONCLUSIONS: GARP-LTGFβ plays a key role in the development and prognostics of GBM, and GARP-targeted CAR-T therapy shows promising efficacy and safety in murine orthotopic GBM models. A first-in-human phase I clinical trial for patients with recurrent GBM began to enroll patients in May 2025 (NCT06964737).
引用
- Wu BX, Kreatsoulas D, Cam H, et al. Targeting TGFβ docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma. Neuro Oncol. 2025. PMID: 40873341. doi:10.1093/neuonc/noaf195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。